Mobile Health Intervention for Breast Cancer
Recruiting at 3 trial locations
IG
Overseen ByIlana Graetz, PhD
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: Emory University
Must be taking: Capecitabine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Trial Summary
What is the purpose of this trial?
This clinical trial evaluates the feasibility and acceptability of a mobile health device in improving oral chemotherapy adherence in women with triple negative breast cancer that has not spread to other places in the body (non-metastatic). A mobile health device, called SMRxT smart pill bottle may help doctors to remind patients to take medicine on time and monitor their symptoms.
Research Team
IG
Ilana Graetz, PhD
Principal Investigator
Emory University Hospital/Winship Cancer Institute
Eligibility Criteria
This trial is for English-speaking women over 18 with non-metastatic triple negative breast cancer who are prescribed capecitabine/Xeloda. Participants must be able to follow study procedures, have text messaging on their mobile phone, and understand the study's risks and benefits.Inclusion Criteria
I am prescribed capecitabine/Xeloda.
Evidence of an online informed consent indicating awareness of the risk and benefits of study participation
I have been diagnosed with breast cancer.
See 4 more
Exclusion Criteria
My daily activity is significantly limited due to my health.
Those who do not receive their capecitabine/Xeloda prescription until a month after enrollment
Treatment Details
Interventions
- Mobile Health Device
Trial OverviewThe trial tests if a smart pill bottle (SMRxT) can help patients take oral chemotherapy on time and monitor symptoms. It assesses how practical and acceptable this mobile health device is for improving medication adherence.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Group I (SMRxT smart pill bottle)Experimental Treatment4 Interventions
Patients receive a SMRxT smart pill bottle, report symptoms weekly, and receive reminders for missing or incorrect dose for standard of care 3-week capecitabine/Xeloda treatment cycles.
Group II: Group II (standard of care)Active Control3 Interventions
Patients receive a SMRxT smart pill bottle and standard of care.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor
Trials
1,735
Recruited
2,605,000+
National Cancer Institute (NCI)
Collaborator
Trials
14,080
Recruited
41,180,000+
National Institutes of Health (NIH)
Collaborator
Trials
2,896
Recruited
8,053,000+
NRG Oncology
Collaborator
Trials
242
Recruited
105,000+
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.